Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Neoadjuvant androgen deprivation therapy in men with high-risk localized prostate cancer

Rana McKay • 28 May 2020
ASCO 2020
Prostate Cancer Abiraterone Apalutamide Leuprolide Prednisone

Rana R. McKay, MD, of UC San Diego Health, La Jolla, CA, discusses results of a phase II study evaluating abiraterone + prednisone + apalutamide + leuprolide (APAL) or abiraterone + prednisone + leuprolide (APL) in the neoadjuvant setting prior to radical prostatectomy for high risk, localized, prostate cancer patients (NCT02903368). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Rana McKay

5:10
CheckMate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for RCC
Rana McKay • 17 Feb 2021
3:53
Homologous recombination repair pathway alterations in mHSPC
Rana McKay • 17 Feb 2021
5:41
Biomarker analysis of olaparib with or without cediranib in mCRPC
Rana McKay • 17 Feb 2021
8:49
Nivo + ipi in RCC: OMNIVORE
Rana McKay • 28 May 2020

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals